Company Overview and News
Stop missing out on important events!
Our Bureau Shares of Claris Lifesciences will be delisted from the BSE from March 22, the pharma firm announced on Monday and added that trading in the shares will be stopped from March 15. (36-0)
Mumbai: Private equity funds Carlyle Group and Advent International are poised to submit binding offers to buy a minority stake in Mankind Pharma Ltd, according to two people familiar with the matter. (12-0)
The delisting offer to the shareholders of Claris Lifesciences will open on Monday at the BSE. The company, which fixed the floor price at ₹351.60, plans to buy 2.72 crore shares from the public. The open offer closes on February 20. Shares of the company are not listed on the NSE. Non-promoters, including East Bridge Capital, Goldman Sachs, Cobra India and Morgan Stanley, currently hold 49.87 per cent stake in Claris Lifesciences. (12-0)
Among these are ABG Shipyard, Advanced Enzyme, Apollo Tyres, Berger Paints, Castrol India, Century Enka, Claris Lifesciences, Dish TV, Future Retail, Gujarat Alkalies, Heritage Food, Hero MotoCorp, JSW Energy, Kamat Hotels, KEC International, Lupin, Monsanto, Natco Pharma, Noida Toll, PNB, Praj, Ramco, RECL, Siemens, Skipper, Tata Chemicals, Thermax, TN Petro and Wheels India. (9-0)
KiviHealth, a technology platform that aims to create next-generation medical clinic using intelligence and automation, has raised $400,000 in pre-Series A round from Chandigarh Angels Network and Claris Capital, a wholly owned subsidiary of Ahmedabad-based pharma company Claris Lifesciences.
Claris Lifesciences today said it has received a letter from the promoter Athanas Enterprise Pvt Ltd to consider delisting of shares of the pharma company from the stock exchange. (0-1)
Mumbai: Torrent Pharmaceuticals Ltd is likely in advanced discussions to acquire the domestic formulations business of Unichem Laboratories Ltd for Rs3,200-3,300 crore, two people aware of the development said on the condition of anonymity. (36-0)
Claris Lifesciences share price gained 2.6 percent intraday Wednesday after the Reserve Bank of India has allowed foreign investors to raise their stake in the company to 49 percent.
Foreign Institutional Investors (FIIs)/Foreign Portfolios Investors (FPIs) investment limit under Portfolio Investment Scheme in Claris Lifesciences Ltd has increased from 24%to 49% of its paid-up capital," the RBI said in a notification
10:00 am Listing: MAS Financial Services share price started off trade with a whopping premium of 44 percent on the National Stock Exchange. (25-0)
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in “National Do Not Call Registry” as laid down by “Telecom Regulatory Authority of India” will not be applicable for such information/ communication. (4-0)
Drug maker Claris Lifesciences said its net cash availability stands at Rs 2077 crore translating to Rs 381 per every single share, without considering taxes. (0-1)
Ahmedabad-headquartered Claris Lifesciences that recently completed the sale of its remaining 20 per cent stake in Otsuka Pharmaceutical India Private Limited (OPIPL), the joint venture with Otsuka Pharmaceutical Factory and Mitsui & Co, to Otsuka, on Thursday said that it is considering options (dividend or share buyback) to distribute around Rs 2,077 crore to its shareholders. In a filing to the BSE, Claris Lifesciences said that the total cash available with the company is Rs 3,614 crore.
It was a spectacular rally in late trade Thursday as the Sensex surged 375 points and the Nifty reclaimed 10,100 level intraday, backed by Reliance Industries, private banks, FMCG and metals stocks. The broader markets also participated in the rally, rising for the second consecutive session. (9-0)
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in “National Do Not Call Registry” as laid down by “Telecom Regulatory Authority of India” will not be applicable for such information/ communication.